1 / 25

BREAST CANCER

BREAST CANCER Curtis Tucker M.D. Epidemiology 32% of all female cancers 15% of cancer deaths 217,000 new cases per year 40,500 deaths per year Risk Factors FEMALE Increasing age – very uncommon below the age of 40, but risk increases to 1 in 8 for women living into their 80’s

Sophia
Télécharger la présentation

BREAST CANCER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BREAST CANCER Curtis Tucker M.D.

  2. Epidemiology • 32% of all female cancers • 15% of cancer deaths • 217,000 new cases per year • 40,500 deaths per year

  3. Risk Factors • FEMALE • Increasing age – very uncommon below the age of 40, but risk increases to 1 in 8 for women living into their 80’s • Family history – relative risk is 1.7 if women have a first degree relative with breast cancer • Proliferative breast disease- ductal hyperplasia, sclerosing adenosis, lobular hyperplasia, LCIS • Personal history of breast cancer (also colon, ovarian, endometrial) • Reproductive factors • Radiation exposure, especially at early age • ?? HRT • Alcohol, high fat diet, obesity

  4. Genetic Risk Factors • Hereditary forms of breast cancer account for only 5% of breast cancer cases • BRCA1 mutation – inherited AD fashion with a lifetime risk of breast cancer of ~55% - 85% and ovarian cancer risk of ~15 – 45% • BRCA2 mutation – 6% lifetime risk of breast cancer

  5. Screening • Breast self-exams – beginning in their 20’s • Clinical breast exam – beginning at age 20 q 3 yrs and annually after age 40 (15% of breast cancers detected only clinically) • Mammography – annually beginning at age 40 or 5-10 yrs prior to any first degree relatives dx age (85% of tumors mammographically detectable) 50% of lesions dtected by mammo only • Screening US for dense breasts • ?? Breast MRI

  6. Signs and Symptoms • Mammo findings – microcalcifications, asymmetry, mass, architectural distortion most DCIS found on mammo only • Breast lump – 65% of cases • Eczematoid changes in the nipple (Paget’s dz) • Nipple retraction/discharge • Skin changes/ulceration

  7. Pathology • Ductal Carcinoma In Situ (DCIS) - 25% of cases • Infiltrating Ductal Carcinoma – 65% of cases • Infiltrating Lobular Carcinoma – 5-10% of cases • Rare types – medullary, tubular, lymphoma, sarcoma

  8. TNM Staging • Tx – tumor cannot be assessed • T0 – no evidence of primary tumor • Tis – DCIS • T1 - tumor less than/equal to 2 cm • T2 - tumor > 2 cm but not > 5 cm • T3 – tumor > 5 cm • T4 – involvement of skin or chest wall or inflammatory carcinoma

  9. TNM Staging • Nx – lymph nodes (LN) cannot be assessed • N0 – No regional LN • N1 – movable axillary LN • N2 – fixed/matted axillary LN or internal mammary LN only • N3 – both axillary and internal mammary LN, or infraclavicular LN or supraclavicular LN

  10. TNM Staging • Mx – metastasis cannot be assessed • M0 – no distant mets • M1 – distant mets

  11. TNM Staging • Stage 0 – DCIS • Stage I – T1 N0 M0 • Stage II – T1 N1 M0 T2 N0-1 M0 T3 N0 M0 • Stage III – T3 N1 M0 any N2-3 M0 any T4 M0 • Stage IV – any M1

  12. Prognostic Factors • TNM staging • Lymph node status – prognosis directly correlates with number of positive LN • Node negative - 20% recurrence at 5 yr • LN+ > 10 nodes – 75% recurrence rate at 5 years • Hormone receptor status – ER/PR positive is more favorable • Her2/neu positive is more unfavorable

  13. Breast Cancer Survival Ratesat 8 years • Stage 0 – 98% • Stage I – 90% • Stage II – 70% • Stage III – 40% • Stage IV – 10%

  14. TreatmentLCIS • Not breast cancer • Marker for increased risk of breast cancer • Lifetime risk of developing breast cancer 25 to 30% • Do not need excisional bx or clear margins • Treatment options – close observation, tamoxifen, bilateral prophylactic mastectomies

  15. Treatment DCIS • Pre-invasive cancer • Risk of LN involvement/distant mets is 1% • Do not need met w/u or LN dissection • Options for tx – breast conserving therapy vs simple mastectomy • Need clear margins for breast conservation

  16. BCT for DCIS • DFS rate at 5 years – 99% • Review of NSABP-06 showed no difference in survival for BCT vs mastectomy • NSABP-17 prospective randomized trial lumpectomy vs lumpectomy and radiation at 8 yrs local recurrence reduced from 27% to 12% with radiation, no difference in survival (no boost) • European trial prospective trial same results • All subgroups showed decrease in local recurrence rate • Addition of tamoxifen further reduced risk (6 year FU 13% recurrence vs 8%)both ipsilateral and contralateral • Do patients need radiation? Yes.

  17. Invasive Breast CancerEarly Stage • Treatment options include BCT vs. modified radical mastectomy

  18. BCT vs Mastectomy • Multiple US and international prospective randomized trials all show equivalency of BCT with radiation to mastectomy (over 4000 patients total) • Largest US trial NSABP-06, 1800 women randomized, 20 year follow up no difference in either local/regional recurrences – 15% mastectomy vs 9% BCT, or in disease-free survival 36% mastectomy vs 35% BCT

  19. BCT vs Mastectomy • This study included an arm with lumpectomy alone and although DFS was not significantly effected (P 0.07) local recurrence rate was 40% • Ability to have is BCT is not affected by LN status and in fact in women with positive LN after mastectomy appear to have a survival benefit with the addition of radiation to the chest wall • Current radiation techniques yield a failure rate in the breast of ~ 4% at 5 years

  20. Breast Conserving TreatmentCriteria • Typically less than 5 cm lesion • No multicentric dz/calcifications • Must have negative margins (>1mm) this includes DCIS • No Scleraderma/autoimmune dz • Breast/tumor proportion – cosmetic outcome

  21. Early Stage Breast CancerAdjuvant Treatment • Chemotherapy • Hormonal therapy – tamoxifen, arimidex, femara, aromasin, raloxifene • Herceptin monoclonal antibody to her2/neu receptor

  22. Advanced Stage Work Up • CBC, CMP • CT chest and upper Abd • Bone scan • Consider PET scan

  23. Advanced StageTreatment • Typically includes surgery, chemotherapy, radiation, and if possible hormonal therapy

  24. Inflammatory Breast Carcinoma • Can present with a cellulitis type picture and usually arises very quickly • Does not typically have a dominant mass • Poor prognosis and must be treated very aggressively • Treated with chemotherapy followed by mastectomy then radiation and more chemotherapy

More Related